Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 4-7 February 2013
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC)held its seventh meeting from 4 to 7 February 2013.
For an overview of all information available following the meeting of the PRAC, please see the table below.
The Agency publishes a new page following the PRAC meeting each month. The minutes of each PRAC meeting will be published during the week following the subsequent PRAC.
View the agenda and other sources here.
Related LinksSAE Rates in Clinical Trials
Telemedicine Considerations When Conducting Decentralized Clinical Trials
January 14th 2025Compliance with state telemedicine requirements is imperative, as not only will most clinical trial sponsors contractually require such compliance, but non-compliance may also subject the practitioner to licensure violations and liability.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
